News
TELA
0.8215
+5.19%
0.0405
Analysts’ Top Healthcare Picks: Argenx Se (ARGX), TELA Bio (TELA)
TipRanks · 1d ago
Analyst Reaffirms Buy on TELA Bio, Citing Restructuring-Driven Cost Savings and Steady $2 Price Target
TipRanks · 3d ago
Morning Movers: SAIC jumps following FY27 guidance hike
TipRanks · 4d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 4d ago
TELA Bio Implements Workforce Cuts and Leadership Changes
TipRanks · 4d ago
TELA Bio Announces $17M Annual Expense Reduction Through 20% Workforce Streamlining and Resource Optimization, Extending Cash Runway Into 2028
Benzinga · 4d ago
TELA Bio COO And CFO Roberto Cuca To Step Down Effective Immediately
Benzinga · 4d ago
*TELA Bio Oper Chief and Chief Fincl Officer Roberto Cuca to Step Down From the Roles
Dow Jones · 4d ago
Press Release: TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative
Dow Jones · 4d ago
Weekly Report: what happened at TELA last week (0824-0828)?
Weekly Report · 4d ago
Weekly Report: what happened at TELA last week (0817-0821)?
Weekly Report · 08/24 09:18
TELA Bio CEO Makes Bold Move Signaling Fresh Confidence in the Company
TipRanks · 08/18 02:02
Weekly Report: what happened at TELA last week (0810-0814)?
Weekly Report · 08/17 09:18
Tela Bio Earnings Call: Growth Meets Execution Risks
TipRanks · 08/16 00:28
Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Sonida Senior Living (SNDA) and TELA Bio (TELA)
TipRanks · 08/11 13:50
Analysts Are Bullish on Top Healthcare Stocks: Hims & Hers Health (HIMS), TELA Bio (TELA)
TipRanks · 08/11 11:10
Piper Sandler Sticks to Its Hold Rating for TELA Bio (TELA)
TipRanks · 08/11 10:57
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
NASDAQ · 08/10 21:55
Tela Bio reports Q2 EPS (20c), consensus (18c)
TipRanks · 08/10 20:45
Tela Bio withdraws FY26 guidance
TipRanks · 08/10 20:45
More
Webull provides a variety of real-time TELA stock news. You can receive the latest news about Tela Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TELA
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.